liotrix

[li´o-triks] a mixture of liothyronine sodium and levothyroxine sodium in a ratio of 1:4 by weight; used for therapy" >replacement therapy in hypothyroidism and for the prophylaxis and treatment of goiter and of thyroid cancer; administered orally as the sodium salt.

liotrix

Thyrolar

Pharmacologic class: Synthetic thyroid hormone

Therapeutic class: Thyroid hormone replacement

Pregnancy risk category A

FDA Box Warning

• Drug has been used (alone or with other agents) to treat obesity. In euthyroid patients, doses within range of daily hormonal requirements are ineffective for weight loss. Larger doses may produce serious or even life-threatening toxicity, particularly when given with sympathomimetic amines (such as those used for anorectic effects).

Action

Increases basal metabolic rate, helps regulate cell growth and differentiation, and enhances metabolism of lipids, proteins, and carbohydrates

Availability

Tablets: 12.5 mcg levothyroxine sodium and 3.1 mcg liothyronine sodium (Thyrolar-¼); 25 mcg levothyroxine sodium and 6.25 mcg liothyronine sodium (Thyrolar-½); 50 mcg levothyroxine sodium and 12.5 mcg liothyronine sodium (Thyrolar-1); 100 mcg levothyroxine sodium and 25 mcg liothyronine sodium (Thyrolar-2); 150 mcg levothyroxine sodium and 37.5 mcg liothyronine sodium (Thyrolar-3)

Indications and dosages

➣ Hypothyroidism

Adults: All dosages individualized. Initially, one tablet Thyrolar-½ P.O., increased by one tablet Thyrolar-¼ P.O. daily until desired effect occurs. Usual maintenance dosage is one tablet Thyrolar-1 or Thyrolar-2 P.O. daily, adjusted within first 4 weeks based on laboratory results.

➣ Congenital hypothyroidism

Children older than age 12: 18.75/75 mcg P.O. daily

Children ages 6 to 11: 12.5/50 to 18.75/75 mcg P.O. daily

Children ages 1 to 5: 9.35/37.5 to 12.5/50 mcg P.O. daily

Children ages 6 to 12 months: 6.25/25 to 9.35/37.5 mcg P.O. daily

Children up to 6 months: 3.1/12.5 to 6.25/25 mcg (Thyrolar-¼) P.O. daily

Dosage adjustment

• Severe, long-standing hypothyroidism

• Cardiovascular disease

• Psychosis or agitation

• Elderly patients

Contraindications

• Hypersensitivity to drug or its components

• Acute myocardial infarction

• Uncorrected thyrotoxicosis

• Uncorrected adrenal insufficiency and coexisting hypothyroidism

Precautions

Use cautiously in:

• cardiovascular disease, severe renal insufficiency, diabetes mellitus, uncorrected adrenocortical disorders

• elderly patients

• pregnant or breastfeeding patients.

Administration

• Know that all dosages are highly individualized.

• Administer single daily dose in morning with or without food.

Adverse reactions

CNS: insomnia, irritability, nervousness, headache

CV: angina pectoris, hypotension, hypertension, increased cardiac output, tachycardia, arrhythmias, cardiovascular collapse

GI: vomiting, diarrhea, cramps

GU: menstrual irregularities

Metabolic: hyperthyroidism

Musculoskeletal: accelerated bone maturation (in children), decreased bone density (with long-term use in women)

Skin: alopecia (in children), diaphoresis

Other: weight loss, heat intolerance

Interactions

Drug-drug. Aminoglutethimide, amiodarone, anabolic steroids, antithyroid drugs, asparaginase, barbiturates, carbamazepine, chloral hydrate, cholestyramine, clofibrate, colestipol, corticosteroids, danazol, diazepam, estrogens, ethionamide, fluorouracil, heparin (with I.V. use), insulin, lithium, methadone, mitotane, nitroprusside, oxyphenbutazone, P-aminosalicyclic acid, perphenazine, phenylbutazone, phenytoin, propranolol, salicylates (large doses), sulfonylureas, thiazides: altered thyroid function test results

Anticoagulants: increased anticoagulant action

Beta-adrenergic blockers (selected): decreased beta blocker action

Cardiac glycosides: decreased cardiac glycoside blood level

Cholestyramine, colestipol: liotrix inefficacy

Theophyllines: decreased theophylline clearance

Drug-diagnostic tests. Thyroid function tests: decreased values

Drug-food. Foods high in iron or fiber, soybeans: decreased drug absorption

Patient monitoring

• Monitor for evidence of overdose, such as signs and symptoms of hyperthyroidism (weight loss, cardiac symptoms, abdominal cramps).

• Watch closely for signs and symptoms of undertreatment.

• In patients with Addison's disease or diabetes mellitus, assess for signs that these conditions are worsening. In diabetic patients, monitor blood glucose level.

• Check vital signs and ECG routinely.

• Monitor thyroid and liver function tests.

• Assess for signs and symptoms of bleeding tendency, especially if patient's taking anticoagulants.

Patient teaching

• Inform patient or parents that drug should be taken in morning with or without food.

• Explain that patient may require lifelong therapy and will need to undergo regular blood testing.

• Advise diabetic patient (or his parents) to monitor patient's blood glucose level closely.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• Inform parents that hair loss may occur in children during first few months of therapy but that this effect is usually transient.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

liotrix

An obsolete therapeutic agent consisting of liothyronine sodium and levothyroxine sodium.

单词	liotrix
释义	liotrix liotrix [li´o-triks] a mixture of liothyronine sodium and levothyroxine sodium in a ratio of 1:4 by weight; used for therapy" >replacement therapy in hypothyroidism and for the prophylaxis and treatment of goiter and of thyroid cancer; administered orally as the sodium salt. liotrix Thyrolar *Pharmacologic class:* Synthetic thyroid hormone *Therapeutic class:* Thyroid hormone replacement *Pregnancy risk category A* FDA Box Warning • Drug has been used (alone or with other agents) to treat obesity. In euthyroid patients, doses within range of daily hormonal requirements are ineffective for weight loss. Larger doses may produce serious or even life-threatening toxicity, particularly when given with sympathomimetic amines (such as those used for anorectic effects). Action Increases basal metabolic rate, helps regulate cell growth and differentiation, and enhances metabolism of lipids, proteins, and carbohydrates Availability Tablets: 12.5 mcg levothyroxine sodium and 3.1 mcg liothyronine sodium (Thyrolar-¼); 25 mcg levothyroxine sodium and 6.25 mcg liothyronine sodium (Thyrolar-½); 50 mcg levothyroxine sodium and 12.5 mcg liothyronine sodium (Thyrolar-1); 100 mcg levothyroxine sodium and 25 mcg liothyronine sodium (Thyrolar-2); 150 mcg levothyroxine sodium and 37.5 mcg liothyronine sodium (Thyrolar-3) Indications and dosages ➣ Hypothyroidism Adults: All dosages individualized. Initially, one tablet Thyrolar-½ P.O., increased by one tablet Thyrolar-¼ P.O. daily until desired effect occurs. Usual maintenance dosage is one tablet Thyrolar-1 or Thyrolar-2 P.O. daily, adjusted within first 4 weeks based on laboratory results. ➣ Congenital hypothyroidism Children older than age 12: 18.75/75 mcg P.O. daily Children ages 6 to 11: 12.5/50 to 18.75/75 mcg P.O. daily Children ages 1 to 5: 9.35/37.5 to 12.5/50 mcg P.O. daily Children ages 6 to 12 months: 6.25/25 to 9.35/37.5 mcg P.O. daily Children up to 6 months: 3.1/12.5 to 6.25/25 mcg (Thyrolar-¼) P.O. daily Dosage adjustment • Severe, long-standing hypothyroidism • Cardiovascular disease • Psychosis or agitation • Elderly patients Contraindications • Hypersensitivity to drug or its components • Acute myocardial infarction • Uncorrected thyrotoxicosis • Uncorrected adrenal insufficiency and coexisting hypothyroidism Precautions Use cautiously in: • cardiovascular disease, severe renal insufficiency, diabetes mellitus, uncorrected adrenocortical disorders • elderly patients • pregnant or breastfeeding patients. Administration • Know that all dosages are highly individualized. • Administer single daily dose in morning with or without food. Adverse reactions CNS: insomnia, irritability, nervousness, headache CV: angina pectoris, hypotension, hypertension, increased cardiac output, tachycardia, arrhythmias, cardiovascular collapse GI: vomiting, diarrhea, cramps GU: menstrual irregularities Metabolic: hyperthyroidism Musculoskeletal: accelerated bone maturation (in children), decreased bone density (with long-term use in women) Skin: alopecia (in children), diaphoresis Other: weight loss, heat intolerance Interactions Drug-drug. Aminoglutethimide, amiodarone, anabolic steroids, antithyroid drugs, asparaginase, barbiturates, carbamazepine, chloral hydrate, cholestyramine, clofibrate, colestipol, corticosteroids, danazol, diazepam, estrogens, ethionamide, fluorouracil, heparin (with I.V. use), insulin, lithium, methadone, mitotane, nitroprusside, oxyphenbutazone, P-aminosalicyclic acid, perphenazine, phenylbutazone, phenytoin, propranolol, salicylates (large doses), sulfonylureas, thiazides: altered thyroid function test results Anticoagulants: increased anticoagulant action Beta-adrenergic blockers (selected): decreased beta blocker action Cardiac glycosides: decreased cardiac glycoside blood level Cholestyramine, colestipol: liotrix inefficacy Theophyllines: decreased theophylline clearance Drug-diagnostic tests. Thyroid function tests: decreased values Drug-food. Foods high in iron or fiber, soybeans: decreased drug absorption Patient monitoring • Monitor for evidence of overdose, such as signs and symptoms of hyperthyroidism (weight loss, cardiac symptoms, abdominal cramps). • Watch closely for signs and symptoms of undertreatment. • In patients with Addison's disease or diabetes mellitus, assess for signs that these conditions are worsening. In diabetic patients, monitor blood glucose level. • Check vital signs and ECG routinely. • Monitor thyroid and liver function tests. • Assess for signs and symptoms of bleeding tendency, especially if patient's taking anticoagulants. Patient teaching • Inform patient or parents that drug should be taken in morning with or without food. • Explain that patient may require lifelong therapy and will need to undergo regular blood testing. • Advise diabetic patient (or his parents) to monitor patient's blood glucose level closely. • Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness. • Inform parents that hair loss may occur in children during first few months of therapy but that this effect is usually transient. • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above. liotrix An obsolete therapeutic agent consisting of liothyronine sodium and levothyroxine sodium.
随便看	european age management network european agency for development in special needs education european agency for health and safety at work european agency for reconstruction european agency for safety and health at work european agency for the evaluation of medicinal products european agent systems summer school european age standardised rate european agreement concerning the work of crews of vehicles engaged in international road transport european agricultural fund for rural development european agricultural guarantee and guidance fund european agricultural guarantee fund european agricultural guidance and guarantee fund european agricultural rural development fund european agri-food network european aids clinical society european aids treatment group european aids treatment news european air chemistry network european aircraft noise services european air force academies european air group european air law association european airlift center european airlift coordination cell